Gilead Sciences has signed a definitive agreement to acquire Tubulis, a clinical-stage biotechnology company based in Germany, to strengthen its oncology portfolio and target areas of high unmet medical need.
The deal significantly expands Gilead’s ADC capabilities, adding platforms designed to deliver diverse payloads more selectively to tumors and maximize patient benefit.
Gilead Sciences will acquire all outstanding equity of Tubulis for $3.15 billion in upfront cash—subject to adjustments—plus up to $1.85 billion in milestone payments, in a deal anticipated to close in Q2 2026. The transaction is subject to regulatory approvals and customary closing conditions.
The acquisition complements Gilead’s existing oncology expertise and development infrastructure.
“The agreement to acquire Tubulis is a significant milestone in Gilead’s progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline,” said Daniel O’Day, Chairman and CEO of Gilead Sciences.
“Today’s agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities. Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company’s history.”
Dominik Schumacher, CEO and Co-founder of Tubulis, added, “From the outset, we believed our conjugation technology platforms could have broad impact across the ADC field and the initial data from TUB-040 have reinforced that conviction."
"Joining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide.
"Through our existing collaboration, Gilead has already seen the potential of our technologies and together, we are well positioned to accelerate the development of our ADC pipeline. I’m deeply grateful to the Tubulis team, our Board of Directors, investors, and partners for their commitment and helping make this milestone possible.”
